PROSPECTIVE , RANDOMIZED PHASE II STUDY 
COMPARING TWO ELUTION RATES OF GLAUKOS 
TRAVOPROST INTRAOCULAR IMPLANTS TO 
TIMOLOL MALEATE OPHTHALMIC SOLUTION , 
USP,  0.5%
PROTOCOL #GC-009 
DOCUMENT CONTROL # AND REVISION #: CR-0412-2015  REV 2 
DATE:  SEPTEMBER 16, 2016 
Sponsor: 
GLAUKOS CORPORATION  
229 Avenida Fabricante │ San Clemente, CA  92672 │ (949) 367-9600 
[STUDY_ID_REMOVED]
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 2 of 91 
TABLE OF CONTENTS 
SUMMARY  .............................................................................................................6 
LIST OF ABBREVIATIONS A ND DEFINITION OF TERMS ......................................10 
1. INTRODUCTION ....................................................................................................11 
2. OBJECTIVE ...........................................................................................................12 
3. CLINICAL HYPOTHESES .....................................................................................12 
4. STUDY DESIGN......................................................................................................12 
4.1.  Description of Study Design  ...............................................................................12 4.2.  Discussion of Study Design   ...............................................................................14 
5. STUDY MEASURES ...............................................................................................14 
5.1.  EFFICACY MEASURE ......................................................................................14 5.2.  SAFETY MEASURES ........................................................................................14 
6. MATERIALS ...........................................................................................................15 
6.1.  STUDY MEDICATIONS ....................................................................................15 
6.1.1. Test Articles ...............................................................................................15 
6.1.2. Control Articles ..........................................................................................17 
6.1.3. Other Articles .............................................................................................17 
7. METHODS  ...........................................................................................................18 7.1.  SUBJECTS ..........................................................................................................18 7.2.  ELIGIBILITY REQUIREMENTS ......................................................................18 
7.2.1. Inclusion Criteria .......................................................................................18 
7.2.1.1. Screening Inclusion Criteria ............................................................18 
7.2.1.2. Baseline Inclusion Criteria ..............................................................20 
7.2.2. Exclusion Criteria ......................................................................................20 
7.2.2.1. Screening Exclusion Criteria ...........................................................20 
7.2.2.2. Baseline Exclusion Criteria .............................................................23 
7.2.3. Criteria for Subject Exit Prior to Study Completion ..................................23 
7.2.3.1. Prior to Randomization ...................................................................23 
7.2.3.2. After Randomization .......................................................................24 
7.2.3.2.1. Subject Lost to Follow-Up .......................................................24 
7.2.4. Study Termination .....................................................................................24 
7.3.  PROCEDURES ..................................................................................................24 
7.3.1. Duration Of Study ......................................................................................24 
7.3.2. Methods To Monitor Subject Compliance .................................................24 
7.3.3. Enrollment..................................................................................................25 
7.3.4. Screening Phase .........................................................................................25 
7.3.4.1. Visit 1 (Screening) ...........................................................................25 
7.3.4.2. Visit 2 (Baseline) .............................................................................26 
7.3.5. Treatment Phase .........................................................................................27 
7.3.5.1. Visit 3 (Operative Exam) ................................................................27 
7.3.5.2. Visit 4 (Day 1-2 Exam) ...................................................................28 
7.3.5.3. Visit 5 (Week 1-2 Exam) .................................................................29 
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 4 of 91 
9.6.1. General Principles of Data Analysis ..........................................................46 
9.6.2. Subject Enrollment and Disposition ..........................................................47 
9.6.3. Subject Demographic and Ba seline Characteristics ..................................47 
9.6.4. Efficacy Analyses ......................................................................................48 
9.6.4.1.Primary Efficacy Analysis ...................................................................48 
9.6.4.2.Sensitivity Analysis .............................................................................48 9.6.4.3.Analysis of Covariates .........................................................................49 9.6.4.4.Subgroup Analysis ...............................................................................49 9.6.4.5.Exploratory Analyses ...........................................................................49 
9.6.5. Safety Analyses ..........................................................................................49 
9.6.5.1.Study Drug Exposure ...........................................................................50 9.6.5.2.Surgical Complications ........................................................................50 9.6.5.3.Adverse Events ....................................................................................50 9.6.5.4.Best Spectacle Corrected Visual Acuity (BSCVA) .............................50 
10. ADVERSE EVENTS ................................................................................................51 
10.1.  Possible Adverse Events from Impl antation of Model G2TR  or Model 
G2TR-           .................................................................................................52 
10.2.  Possible Adverse Events from Travoprost or Timolol ......................................52 
10.3.  Serious Adverse Event .......................................................................................52 
10.4.  Unexpected Adverse Event ................................................................................53 
10.5.  Non-Serious Adverse Event ...............................................................................54 
10.6.  Intercurrent Events Prior to Randomization ......................................................54 
10.7. Follow-up After Adverse Events ........................................................................54 
11. MAINTAINING THE MASK ..................................................................................54 
12. INFORMED CONSENT ..........................................................................................55 
13. INSTITUTIONAL REVIEW ....................................................................................55 
14. CONFIDENTIALITY/PUBLICATION OF THE STUDY ......................................55 
15. STATEMENT OF COMPLIANCE ..........................................................................56 
16. RECORD KEEPING ................................................................................................56 
16.1.  Source Documents .............................................................................................56 
16.2.  Data Collection  .................................................................................................56 
16.3.  Study Supply Accountability .............................................................................57 
16.4.  Record Retention ...............................................................................................57 
17. BIBLIOGRAPHY ..................................................................................................58 
18. APPENDIX A – SCHEDULE OF VISITS AND ASSESSMENTS ........................59 
19. APPENDIX B – OBLIGATIONS OF INVESTIGATORS......................................60 
20. APPENDIX C – ELEMENTS OF INFORMED CONSENT ...................................61 
21. APPENDIX D - DECLARATION OF HELSINKI..................................................63 
22. APPENDIX E – GLAUKOS TRAVOPROST INTRAOCULAR IMPLANT 
SURGICAL INSTRUCTIONS ..........................................................................................68 23. APPENDIX F –1 TRAVATAN PACKAGE  INSERT AND APPENDIX F-2 
TIMOLOL PACKAGE INSERT………………………………………………………...70 24. APPENDIX G – ARTIFICIAL TEARS PACKAGE INSERT ................................81 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 5 of 91 
25. APPENDIX H – ASSIGNING SUBJECT NUMBERS AND KITS ........................82 
26. APPENDIX I – PROCEDURES FOR EXAMINATIONS ......................................83 
26.1.  Pregnancy Test   .................................................................................................83 
26.2.  Visual Acuity     .................................................................................................83 
26.2.1.  Pinhole Visual Acuity ...............................................................................83 
26.2.2.  Manifest Refraction and Best Sp ectacle Corrected Visual Acuity 
(ETDRS)   .................................................................................................83 
26.3.  Pachymetry…… ................................................................................................84 
26.4.  Gonioscopy…… ................................................................................................84 
26.5.  Slit-lamp Biomicroscopy ...................................................................................84 
26.6.  Intraocular Pressure (IOP) .................................................................................86 
26.6.1. Standard IOP Measurement .......................................................................86 
26.6.2. Diurnal IOP Measurement .........................................................................86 
26.7.  Ophthalmoscopy ................................................................................................86 
26.8.  Visual Field ….. .................................................................................................87 
26.9.  Specular Microscopy .........................................................................................87 
26.10.  Conjunctival Hyperemia, Iris, Eyel ash and Periorbital Assessments and 
Photographs and Blood Sampling ... ................................................................88 
26.10.1. Conjunctival Hyperemia ......................................................................88 
26.10.2. Iris (Color) Assessment ........................................................................88 
26.10.3. Eyelash (Length and Density) Assessment ..........................................89 
26.10.4. Periorbital Assessment .........................................................................89 
26.10.5. Blood Sampling ...................................................................................89 
 
 
  
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 7 of 91 
 
Objective: 
To compare the safety and initial efficacy of intraocular implants containing travoprost at 
two different elution rates versus Timolo l Maleate Ophthalmic Solution, USP, 0.5% 
(timolol) in reducing elevated intraocular pre ssure in subjects with  open-angle glaucoma 
(OAG) or ocular hypertension (OHT).   
 
Clinical Hypotheses: 
‐ Intraocular implants containing travoprost are at least as effective as timolol in 
achieving lowered intraocular pressure  (IOP) in subjects with open-angle 
glaucoma (OAG) or ocular hypertension (OHT) 
‐ Intraocular implants containing travoprost are well-tolerated 
 
Study Population: Approximately 150 subjects diagnosed with  OAG or OHT will be randomized. Subjects 
must meet all entry criteria at the Screening Visit. Subj ects on 0 medications at the 
Screening Visit must have an IOP of  in the study eye, and then complete a 
3-day waiting period and return for a Baseline exam. Subjects on 1-3 medications must complete a required medication washout/waiting period. At the Baseline visit, all subjects 
must have mean diurnal IOP of  in the study eye, and meet all other entry 
criteria. 
 
Structure: parallel groups 
 
Multicenter: Yes  
Masking: 
‐ Observer-masked (IOP readings, assessments of 
symptomatology) 
‐ Subject-masked 
 
Method of Subject Assignment: After the 4:00 pm IOP measurement at Visi t 2 (Baseline), qualified subjects will be 
scheduled to undergo treatment with the G2 TR-  implant, the G2TR-  implant, or 
timolol in a ratio of 1:1:1.  Randomization: Yes 
 
Estimated Total Sample Size: Approximately 150 subjects  
Statistical Rationale Provided: Not Applicable 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 9 of 91 
 
 Study Variables and Statistical Analysis: 
Efficacy Variable 
The primary efficacy variable will be the IOP at 1 week through 12 weeks. Refer to the 
Statistical Analysis Section for the statistical an alysis methodology. 
 Safety Variables 
Surgical complications and adverse events will be summarized.  Ocular safety variables, i.e. best spec tacle-corrected visual acuity, biomicroscopy 
findings, gonioscopy findings, ophthalmoscopy findings (including cup/disc ratio), 
pachymetry, visual field test evaluation and endothelial cell parameters, will be summarized. In addition, changes from base line in conjunctival hyperemia, periorbital 
measurements, iris (color) and eyelashes (d ensity and length) will be analyzed, if 
feasible.  Blood plasma testing will be performed to assess systemic exposur e to the implant study 
medication (travoprost free acid).   Analysis Populations 
Refer to Statistical Analysis Section (Section 9).   
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 10 of 91 
LIST OF ABBREVIATIONS A ND DEFINITION OF TERMS 
Abbreviation/Term Definition 
AA Alpha agonist 
AREDs Alpha agonist 
AE Adverse event 
BAK Benzalkonium chloride 
BB Beta blocker 
BSCVA Best spectacle corrected visual acuity 
CAI Carbonic anhydrase inhibitor 
CRF Case report form 
ECD Endothelial cell density 
ETDRS Early Treatment of Diabetic Retinopathy Study 
FDA Food and Drug Administration 
GCP Good clinical practice 
ICH International Conference on Harmonization 
IOP Intraocular pressure 
IRB Institutional Review Board 
ITT Intent-to-treat 
LogMAR Logarithm of the minimum angle of resolution 
MA Medical Affairs 
MedDRA Medical Dictionary  for Regulatory Activities 
mmHg Millimeters of mercury 
OAG Open-angle glaucoma 
OHT Ocular hypertension 
OTC Over the counter 
PG Prostaglandin 
PVG Pharmacovigilance 
SAE Serious adverse event 
SOC System organ class 
TEAC Treatment Emergent Adverse Event 
VF Visual field 
 
  
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 11 of 91 
 
1. INTRODUCTION Glaucoma is a group of eye diseases char acterized by progressive, irreversible and 
largely asymptomatic vision loss caused by optic nerve damage, which is most commonly associated with elevated levels of intraocular pressure. Glaucoma is a 
chronic condition that progresses slowly over long periods of time and can have a 
devastating impact on a patient's vision a nd quality of life. Reducing intraocular 
pressure is the only proven treatment for glaucoma.  
 
Treatment for open-angle glaucoma (OAG) has started traditionally with topical ocular hypotensive medical therapy.  Devel opment of more effective medications has 
increased the popularity of this  approaches as initial tr eatment compared to more 
invasive incisional or drainage device  surgery. Furthermore, the more benign 
medication treatments preserve the ocular tissues in the event that more invasive 
surgical approaches are eventually required. 
 
The various topical ocular medications av ailable to reduce IOP include miotics, β-
adrenergic receptor antagonists ( β-blockers), carbonic anhydra se inhibitors (CAIs), α-
adrenergic receptor agonists ( α-agonists), and prostagla ndin analogues (PGs). The 
PGs are a class of ocular hypotensive agen ts that have been proven effective in 
lowering IOP in subjects with  OAG or OHT. Advantages of this class of medications 
over other classes is that the system ic side effects associated with α-agonists (e.g., dry 
mouth, drowsiness) and β-blockers (e.g., depression, fa tigue, bradycardia) do not 
appear to be associated with PGs.  Furt hermore, the ocular si de effects typically 
associated with a-agonists (e.g., allergic reactions), and chol inergic agents (e.g., 
reduced vision), do not seem to ma nifest with the use of PGs. 
 
In spite of these apparent advantages, PGs have been shown to be associated with 
side effects such as ocular hyperemia,  iris hyperchromia, periorbital atrophy, 
increased eyelash growth, general ocul ar surface discomfort and headache.
1-5 These 
side effects and other factor s including cost, compliance, and the difficulty of proper 
instillation, hinder the proper use of topical medications.6,7 Some patients may 
possess or develop an intolera nce to topical medications. 
 
The Travoprost Intraocular Implant was developed to remove or minimize the problem of patient compliance with prescription medication.  This clinical protocol 
will evaluate two versions of the Tra voprost Intraocular Implant: Model G2TR-  
and Model G2TR- . The implants are iden tical except that they are designed to 
elute travoprost at two differe nt elution rates. For the purposes of this protocol, Model 
G2TR-  is the high elution rate implan t and Model G2TR-  is the low elution 
rate implant).  
 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 27 of 91 
7.3.5.  Treatment Phase 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 28 of 91 
7.3.5.2. Visit 4 (Day 1-2 Exam, 1-2 days) 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 29 of 91 
7.3.5.3. Visit 5 (Week 1-2 Exam, 10 days ± 3) 
 
7.3.5.4. Visit 6 (Week 4 Exam, 28 days ± 3) 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 30 of 91 
 
7.3.5.5. Visit 7 (Week 6 Exam, 42 days ± 3) 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 31 of 91 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 32 of 91 
7 3 5 7  Visit 9 (Month 6 Exam  182 days ± 14) 
7.3.5.8. Visit 10 (Month 9 Exam, 274 days ± 14) 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 33 of 91 
 
 
 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 34 of 91 
7.3.5.10. Visit 12 (Month 15 Exam, 455 days ± 30) 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 35 of 91 
 
7.3.5.11. Visit 13 (Month 18 Exam, 547 days ± 30) 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 36 of 91 
 
7 3 5 12  Visit 14 (Month 21 Exam  637 days ± 30) 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 38 of 91 
7.3.5.15. Visit 17 (Month 30 Exam, 910 days ± 60) 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 39 of 91 
 
 
7.3.5.16. Visit 18 (Month 33 Exam, 1000 days ± 60) 
 
 
7.3.5.17. Visit 19 (Month 36 Exam, 1095 days ± 60) 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 50 of 91 
number of ETDRS will be summarized us ing the statistics for the continuous 
variables. 
 
Additionally, the number and per centage of subjects will be  summarized for each of 
the three treatment groups based on the following VA categories: 
 
 
  
  
  
  
  
  
 
10. ADVERSE EVENTS
 
Adverse events will be monitored throughout  the course of the study, and reported 
on an adverse event (AE) form . Any significant change in a 
subject's condition from baseline, re gardless of causality, is to be 
considered an adverse event, unless the change is determined to be a continuation of a pre-existing c ondition that is documented in the 
subject's medical history. However, a clinically significant increase in frequency or worsening in seve rity of a pre-existing condition 
may indicate an adverse event. In addition, a clinical ly significant 
laboratory finding may also indicate an adverse event.  Lack of 
efficacy of the study treatment for the condition being investigated 
is not an adverse event. Subjects should be asked using a general, 
non-direct question if th ere has been any change  in how they feel 
from the previous visit (e.g., "H ow have you felt since the last 
visit?"). Direct questioning and examination should then be 
performed as appropriate.  If an adverse event occurs, then an AE form must be completed includi ng a description of the event, 
seriousness, severity, onset a nd duration, action taken, outcome, 
and relationship to study medication.   A separate AE Form must be 
completed for each adverse event. All items on the AE form must be completed. 
 
If an adverse event is ongoi ng at the time of study exit, th en the investigator should 
perform reasonable follow-up efforts as n ecessary (e.g., telephone contact, post-study 
office visit) to determine the outcome of the event. 
 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 55 of 91 
 
15. STATEMENT OF COMPLIANCE 
This study will be conducted in compliance with the protocol, good clinical practices 
(GCP), International Conference on Harmoniza tion (ICH) guidelines, the Declaration of 
Helsinki, and applicable regulatory requirements.  16. RECORD KEEPING 16.1.  Source Documents 
The clinical investigator must maintain detailed source documents on all study subjects. Source documents include subject medical r ecords, hospital charts, clinic charts, 
investigator subject study file s, as well as the results of diagnostic tests (e.g., laboratory 
tests, visual fiel d test printouts). 
 
The following minimum information should be  entered into the subject's medical 
record: 
‐ The date the subject entered th e study and the subject number 
‐ The study protocol number and the name of Glaukos 
‐ The date that informed consent was obtained 
‐ Evidence that the subject meets study eligibility requirements (e.g., medical 
history, study procedures  and/or evaluations) 
‐ The dates of all study related subject visits 
‐ Evidence that required procedures and/or evaluations were completed 
‐ Use of any concurrent medications 
‐ Documentation of study medication acc ountability, including a copy of study 
medication labels 
‐ Occurrence and status of  any adverse events 
‐ The date the subject exited the study, a nd a notation as to whether the subject 
completed the study or was discon tinued, including the reason for 
discontinuation 
   
16.2.  Data Collection  
The clinical investigator must maintain detaile d records on all enrolled subjects.  Data for 
enrolled subjects will be collected with an el ectronic data capture system. The electronic 
database, which is Title 21 CFR Part 11 compliant, will be managed by a data management vendor. Access to the database w ill be granted to authorize study personnel 
based on their role after training; and the access will be password-protected. The data clarification process will be ma naged within the electronic data capture system by either 
system-generated or manually generated elect ronic queries. Accuracy of data will be 
verified by 100% source data ve rification at regular intervals,  and all corrections to data 
will be made in the database. 
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 56 of 91 
 
Exit forms are completed for all enrolled subjec ts, regardless of their final study status 
(e.g., subject discontinuation, study termination). 
 
16.3.  Study Supply Accountability 
The principal investigator is responsible fo r ensuring that an inventory is conducted upon 
receipt of the clinical supplies and that the clinical study supplies are received and stored 
as instructed. The receipt of clinical supplie s should be completed, signed, and returned 
as directed by Glaukos (or designee). A copy must be maintained at the site for the 
investigator's records. The principal invest igator will keep a current record of the 
inventory and dispensing of all study medicati ons. This record will be made available to 
the Glaukos monitor (or designee) for the purpo se of accounting for all clinical supplies. 
Any significant discrepancy and/or deficiency must be record ed with an explanation. All 
supplies sent to the investigator must  be accounted for and in no case will study 
medications be used in any unauthorized situation. 
 It is the responsibility of the principal investigator to return any used and unused supplies 
to the Glaukos monitor (or designee)  at the conclusion of the study. 
 
16.4.  Record Retention 
All records relating to the conduct of this study are to be retained by the investigator until 
notified by Glaukos that the records may be destroyed.  The investigator will allow re presentatives of Glaukos' m onitoring team (or designee), 
the governing institutional re view board, the Food and Drug Administration (FDA), and 
other applicable regulatory agencies to  inspect all study records, CRFs, and 
corresponding portions of the s ubject's office and/or hospital medical records at regular 
intervals throughout the study. These inspecti ons are for the purpose of verifying 
adherence to the protocol, completeness, and exactness of the data being entered onto the 
CRF, and compliance with FDA or ot her regulatory agency regulations. 
  
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 58 of 91 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 59 of 91 
  
19. APPENDIX B - OBLIGATIONS OF INVESTIGATORS 
 
In summary, the clinical investigator has agreed to the following obligations: 
‐ Obtaining informed consent from ever y subject prior to enrollment in the 
study and maintaining records of cons ent as part of the study records. 
‐ Obtaining approval from the Institu tional Review Board (IRB) before 
enrolling any subject; submitting verificat ion of the approval to the Sponsor; 
submitting periodic progress reports (at least annually) and final report to IRB. 
‐ Approving the protocol and conducting th e study according to the protocol 
and applicable regulations; informing the Sponsor of all deviations from the protocol. 
‐ Informing the IRB of all protocol amendments/modifications; sending the 
Sponsor a copy of the letter from the IRB approving the amendment/modification. 
‐ Reporting to the Sponsor and the IRB a ny adverse experiences that occur in 
the course of the investigation. 
‐ Keeping careful and accurate records of all clinical study data (study records 
must be considerably more exact and co mplete than those kept in ordinary 
medical practice); maintaining records of all materials submitted to the IRB 
and of all action by the IRB regarding the study. 
‐ Making study records available for in spection by the sponsor (Glaukos) and 
representatives of the Food and Drug Administration; keeping records until notified by the Sponsor that they may be destroyed. 
‐ Maintaining proper control and documentation of all test and control articles. 
‐ Submitting the following records and repor ting to the Sponsor (See I, II, and 
III). 
 
I. Prior to the Beginning of the Study 
‐ A signed Form FDA-1572 or Statement of Investigator. 
‐ A current curriculum vitae (CV) if not  submitted to Glaukos previously or 
if updated. 
‐ CVs for all sub-investigators listed on the 1572. 
‐ A letter from the Institutional Review Board (IRB) indicating that the protocol was approved, including th e name and address of the IRB. 
‐ A copy of the consent form approved by IRB. 
‐ A list of current members of the IRB. 
 
II. While the Study is in Progress 
‐ Acknowledgment of receipt of the test and control articles; documentation of disposition of all te st and control articles. 
‐ Original Case Report Forms for each subject enrolled in the study. 
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 60 of 91 
‐ Information regarding all devi ations from the protocol. 
‐ Information regarding all adverse medi cal events occurring to a subject 
while enrolled in the study. 
‐ Annual progress report (if study is ongoing for more than one year). Letter 
from the IRB indicating approval of the annual progress report. 
 
III. Once the Study is Completed 
‐ Disposition of all used and/or unused test and control ar ticles, as well as 
documentation of all drug accountability. 
‐ A final study report (if requested). 
 20. APPENDIX C - ELEMENTS OF INFORMED CONSENT 
I. Elements of Informed Consent The following information must be pr ovided to each subject in obtaining 
informed consent. If written consent is being obtained, the subject (or subject's 
legal representative) should be provid ed with a copy of the signed written 
informed consent. 
 
1. State that the study involves RESEARCH. 
 
A. Explain the PURPOSE of the research. 
B. State the expected DURATION of the subject's participation. 
C. Describe the PROCEDURES to be followed. 
D. Identify any EXPERIMENTAL procedures. 
 
2. Describe any reasonably foreseeable RI SKS OR DISCOMFORTS to the subject. 
 
3. Describe any BENEFITS to the subject or to others that  may reasonably be 
expected from the research. 
 
4. Note appropriate ALTERNATIVE procedures or courses of  treatment, if any that 
might be advantageous to the subject. 
 
5. a. Describe the extent, if any, to  which CONFIDENTIALITY of records 
identifying the subject will be maintained. 
b. Note that the Food and Drug Admini stration MAY INSPECT the records. 
 
6. For research involving more than mini mal risk, explain if any COMPENSATION 
or medical treatments are available should injury occur. If so, explain (a) what 
they consist of, OR (b) where furt her information may be obtained. 
 
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 61 of 91 
7. a. Tell whom to contact for ANSWERS to pertinent questi ons about (a) the 
research, and (b) resear ch subjects’ rights. 
b. Tell whom to contact in the event of  a research-related INJURY to the 
subject. 
 
8. State that: 
a. Participation is VOLUNTARY, 
b. Refusal to participate will involve NO PENALTY or loss of benefits to 
which the subject is otherwise entitled, and 
c. The subject MAY DISCONTINUE particip ation at any time without penalty 
or loss of benefits to which the subject is otherwise entitled. 
 
II. Additional Elements of Informed Consent 
 When appropriate, one or more of the followi ng elements of information shall also be 
provided to each subject:  
1. A statement that particular treatment or procedure may involve risks to the 
subject (or to the embryo or fetus, if the subject is or may become pregnant) 
which are currently unforeseeable. 
2. Anticipated circumstances under which the subject's participation may be 
terminated by the investigator withou t regard to the subject's consent. 
3. Any additional costs to the subject that may result from participation in the research. 
4. The consequences of a subject's decisi on to withdraw from  the research and 
procedures for orderly termination of participation by the subject. 
5. A statement that significant new findings  developed during the course of the 
research, which may relate to the subject's  willingness to continue participation, 
will be provided to the subject. 
6. The approximate number of s ubjects involved in the study. 
 The informed consent requirements in these regulations are not intended to preempt any 
applicable Federal, State, or local laws which require additional information to be 
disclosed for informed consent to be legally effective.  
Nothing in these regulations is intended to limit the authority of a physician to provide 
emergency medical care to the extent the physician is permitted to do so under applicable 
Federal, State, or local law.  REFERENCE: 21 CFR Part 50.25 - PROTECTION OF HUMAN SUBJECTS, Elements of informed consent. 
  
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 62 of 91 
21. APPENDIX D - DECLARATION OF HELSINKI 
 
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI 
Ethical principles for medical re search involving human subjects 
Adopted by the 18th WMA General Assembly Helsinki, Finland, June 1964 and amended 
by the 29th WMA General Assembly, Tokyo, Japan, October 1975 35th WMA General 
Assembly, Venice, Italy, October 1983 41st WMA General Assembly, Hong Kong, 
September 1989 48th WMA General Assembl y, Somerset West, Republic of South 
Africa, October 1996 and the 52nd WMA 
General Assembly, Edinburgh, Scotland, October 2000 
 
A. INTRODUCTION 
1. The World Medical Association has devel oped the Declaration of Helsinki as 
a statement of ethical principles to provide guidance to physicians and other 
participants in medical research invo lving human subjects. Medical research 
involving human subjects includes research on identifiable human material or 
identifiable data. 
2. It is the duty of the physician to pr omote and safeguard the health of the 
people. The physician’s knowledge and conscience are dedicated to the 
fulfillment of this duty. 
3. The Declaration of Geneva of the World Medical Association binds the 
physician with the words, "The health  of my patient will be my first 
consideration," and the International Code of Medical Ethics declares that, "A 
physician shall act only in the patient's interest when providing medical care 
which might have the effect of weakening the physical and mental condition 
of the patient." 
4. Medical progress is based on research wh ich ultimately must rest in part on 
experimentation involv ing human subjects. 
5. In medical research on human subjects, considerations related to the well-
being of the human subject should ta ke precedence over the interests of 
science and society. 
6. The primary purpose of medical resear ch involving human subjects is to 
improve prophylactic, diagnostic and therapeutic pro cedures and the 
understanding of the aetiology and pathoge nesis of disease. Even the best 
proven prophylactic, diagnos tic, and therapeutic met hods must continuously 
be challenged through research  for their effectiveness, efficiency, accessibility 
and quality. 
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 63 of 91 
7. In current medical practice and in medical research, most prophylactic, 
diagnostic and therapeutic proce dures involve risks and burdens. 
8. Medical research is subject  to ethical standards that  promote respect for all 
human beings and protect their health and rights. Some research populations 
are vulnerable and need special protection. The particular needs of the 
economically and medically disadvantaged must be recognized. Special 
attention is also required for those who cannot give or refuse consent for 
themselves, for those who may be subject  to giving consent under duress, for 
those who will not benefit personally from the research and for those for 
whom the research is combined with care. 
9. Research Investigators s hould be aware of the ethi cal, legal and regulatory 
requirements for research on human subjec ts in their own countries as well as 
applicable international requirements. No  national ethical, legal or regulatory 
requirement should be allowed to reduce or eliminate any of the protections 
for human subjects set fort h in this Declaration. 
 
B. BASIC PRINCIPLES FOR ALL MEDICAL RESEARCH 
1. It is the duty of the physician in medical  research to protect  the life, health, 
privacy, and dignity of the human subject. 
2. Medical research involving human s ubjects must conform to generally 
accepted scientific principles, be based on a thorough knowledge of the 
scientific literature, other relevant sources of information, and on adequate 
laboratory and, where appropriate, animal experimentation. 
3. Appropriate caution must be exercised in  the conduct of research which may 
affect the environment, and the welfare of animals used for research must be 
respected. 
4. The design and performance of each e xperimental procedure involving human 
subjects should be clearly formulated in an experimental protocol. This 
protocol should be submitted for co nsideration, comment, guidance, and 
where appropriate, approval to a specially appointed ethical review 
committee, which must be independent of  the investigator, the sponsor or any 
other kind of undue influence. This independent committee should be in 
conformity with the laws and regulations  of the country in which the research 
experiment is performed. The comm ittee has the right to monitor ongoing 
trials. The researcher has the obligati on to provide monitoring information to 
the committee, especially any serious adverse events. The researcher should 
also submit to the committee, for review, information regarding funding, 
sponsors, institutional affiliations, othe r potential conflicts of interest and 
incentives for subjects. 
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 64 of 91 
5. The research protocol should always contain a statement of the ethical 
considerations involved and should indicat e that there is co mpliance with the 
principles enunciated in  this Declaration. 
6. Medical research involving human s ubjects should be conducted only by 
scientifically qualified persons and under the supervision of a clinically 
competent medical person. The responsib ility for the human subject must 
always rest with a medically qualified person and never rest on the subject of 
the research, even though the subject has given consent. 
7. Every medical research project involvi ng human subjects should be preceded 
by careful assessment of predictable ri sks and burdens in comparison with 
foreseeable benefits to the subject or to others. This does not preclude the 
participation of healthy volunteers in medical research. The design of all 
studies should be publicly available. 
8. Physicians should abstain from engagi ng in research projects involving human 
subjects unless they are c onfident that the ri sks involved have been adequately 
assessed and can be satisfactorily ma naged. Physicians should cease any 
investigation if the risks are found to outweigh the pot ential benefits or if 
there is conclusive proof of positive and beneficial results. 
9. Medical research involving human subj ects should only be conducted if the 
importance of the objective outweighs th e inherent risks and burdens to the 
subject. This is especially important when the human subjects are healthy 
volunteers. 
10. Medical research is only ju stified if there is a r easonable likelihood that the 
populations in which the research is car ried out stand to benefit from the 
results of the research. 
11. The subjects must be volunteers and info rmed participants in the research 
project. 
12. The right of research subjects to safe guard their integrity must always be 
respected. Every precaution should be ta ken to respect the privacy of the 
subject, the confidentiality of the patient’s information and to minimize the 
impact of the study on the subject's phys ical and mental integrity and on the 
personality of the subject. 
13. In any research on human beings, each potential subject must be adequately 
informed of the aims, methods, source s of funding, any possi ble conflicts of 
interest, institutional affiliations of the researcher, the anticipated benefits and 
potential risks of the study and the discomfort it may entail. The subject 
should be informed of the right to abstain from partic ipation in the study or to 
withdraw consent to participate at an y time without reprisal. After ensuring 
that the subject has understood the in formation, the physician should then 
obtain the subject's freely given informed consent, preferably in writing. If the 
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 65 of 91 
consent cannot be obtained in wri ting, the non-written consent must be 
formally cumented and witnessed. 
14. When obtaining informed consent for the research project the physician 
should be particularly cautious if the subject is in a dependent relationship 
with the physician or may consent under duress. In that case the informed 
consent should be obtained by a well-i nformed physician who is not engaged 
in the investigation and who is comple tely independent of this relationship. 
15. For a research subject who is legally incompetent, physically or mentally 
incapable of giving consent or is a legally incompeten t minor, the investigator 
must obtain informed consent from the legally authorized representative in 
accordance with applicable law. Thes e groups should not be included in 
research unless the research is neces sary to promote the health of the 
population represented and this research cannot instead be performed on 
legally competent persons. 
16. When a subject deemed legally incompetent, such as a minor child, is able to 
give assent to decisions a bout participation in resear ch, the investigator must 
obtain that assent in addition to th e consent of the le gally authorized 
representative. 
17. Research on individuals from whom it is not possible to obtain consent, 
including proxy or advance consen t, should be done only if the 
physical/mental condition that prevents  obtaining informed consent is a 
necessary characteristic of the research population. The specific reasons for 
involving research subjects with a cond ition that renders them unable to give 
informed consent should be stated in the experimental protocol for 
consideration and approval of the review  committee. The protocol should state 
that consent to remain in the research should be obtained as soon as possible 
from the individual or a le gally authorized surrogate. 
18. Both authors and publishers have ethi cal obligations. In publication of the 
results of research, the investigators are obliged to preserve the accuracy of 
the results. Negative as well as positive results should be published or 
otherwise publicly available. Sources of  funding, institutional affiliations and 
any possible conflicts of interest s hould be declared in the publication. 
Reports of experimentation not in accord ance with the principles laid down in 
this Declaration should not be accepted for publication. 
 
 
 
 
 
 
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 66 of 91 
C. ADDITIONAL PRINCIPLES FOR MEDICA L RESEARCH COMBINED WITH 
MEDICAL CARE 
1. The physician may combine medical resear ch with medical care, only to the 
extent that the research is justified by its potential prophylactic, diagnostic or 
therapeutic value. When medical resear ch is combined with medical care, 
additional standards apply to protect th e patients who are research subjects. 
2. The benefits, risks, burdens and eff ectiveness of a new method should be 
tested against those of the best current prophylactic, diagnostic, and 
therapeutic methods. This does not exclude the use of placebo, or no 
treatment, in studies where no proven prophylactic, diagnostic or therapeutic 
method exists. 
3. At the conclusion of the study, every pa tient entered into the study should be 
assured of access to the best proven prophylactic, diagnostic and therapeutic 
methods identified by the study. 
4. The physician should fully inform the pa tient which aspects of the care are 
related to the research. Th e refusal of a patient to participate in a study must 
never interfere with the pa tient physician relationship. 
5. In the treatment of a patient, wh ere proven prophylactic, diagnostic and 
therapeutic methods do not ex ist or have been ineff ective, the physician, with 
informed consent from the patient, must be free to use unproven or new 
prophylactic, diagnostic and therapeutic measures, if in the physician’s 
judgment it offers hope of saving life, re-establishing health  or alleviating 
suffering. Where possible, these measures should be made the object of 
research, designed to eval uate their safety and e fficacy. In all cases, new 
information should be recorded and, wh ere appropriate, published. The other 
relevant guidelines of this Declaration should be followed. 
 
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 67 of 91 
22. APPENDIX E – GLAUKOS TRAVOPROST INTRAOCULAR IMPLANT 
SURGICAL INSTRUCTIONS 
 
Do not use the implant if the Tyvek lid on the blister tray has been opened or the 
packaging appears damaged.  In such cases, the sterility of the implants may be 
compromised.  
Surgical Instructions 
1. The eye should be anesthetized using general, retrobulbar, peribulbar, or 
topical anesthesia per standard hos pital or ambulatory surgery center 
procedures. 
2. It is recommended that the implant surg ery be performed from the temporal 
side, using a temporal clear corneal incision, to provide clear access for the 
surgical instruments.  The implant w ill be implanted through the trabecular 
meshwork on the nasal side.  
3. Create a clear corneal incision at the temporal limbus location using an 
instrument of the surgeon’s choice. 
4. A cohesive viscoelastic is added to the anterior chamber as needed to improve 
visualization of the angle, and to ma intain IOP for use of the gonioscope.  
5. A gonioscope is placed on the cornea and the surgical microscope and the patient are positioned as needed to visualize the angle, through the gonioprism, on the nasal side of the eye.  Tilting the patient’s head as far as 
practical away from the surgeon, and also tilting the microscope toward the surgeon will help viewing of the angle. 
6. The angle is inspected using a gonioprism  to ensure good visualization at the 
nasal implant location.   
7. Remove the G2TR  or G2TR- on its inserter from the blister tray. Inspect the implant on the tip of the inserter. 
8. When ready for implantation, remove safety clip which holds trigger in place. Keep finger on trigger button to ensure it remains in the forward position and 
doesn’t prematurely release implant. 
9. Insertion of Model G2TR-  or G2TR-   
a. Deepen the anterior chamber with additional viscoelastic to aid in 
chamber maintenance as needed. 
b. Enter the anterior chamber with th e implant using supplied inserter. 
c. Advance to the pupillary margin be fore replacing the goniolens onto 
the eye. 
d. Care must be taken to avoid contact with the lens or cornea. 
e. Advance to the anterior chamber angle and approach the trabecular meshwork.   
f. Press the distal end of the implant directly into an d through trabecular 
meshwork until the barb at the tip securely penetrates the sclera at the outer wall of Schlemm’s canal, a nd the base of the cylindrical 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 68 of 91 
reservoir is firmly in contact with and compressing the trabecular 
meshwork. 
g. During scleral penetration, it may be  necessary to apply firm and 
focused responsive pressure against the sclera on the outside of the eye to react against the penetration a nd keep the tissue from collapsing 
around the sharp tip of the implant thereby preventing penetration. 
h. Once the tip barb of the implant is securely embedded in sclera, carefully slide the trigger button re arward to open the jaws of the 
gripper and thus release the implan t from the inserter.  Back the 
inserter away from the implant with out allowing it to pull the implant 
of position. 
i. Withdraw the insertion in strument from the eye. 
 
10. High-magnification examination is performed to confirm that the implant is in 
proper position (i.e., the proximal end rest s in the anterior chamber with an 
unobstructed membrane) and securely atta ched with the tip barb thoroughly 
embedded in sclera. 
11. It is normal for an edge of the implant to make contact with iris, but most of 
the membrane should be unobstructed by iris. 
12. The anterior chamber is irrigated and aspirated with balanced salt solution (BSS) through the corneal wound to rem ove all viscoelastic.  The surgeon 
may press down on the posterior edge of the incision as needed to facilitate 
complete removal of viscoelastic. 
13. The anterior chamber is inflated with saline solution as needed to achieve physiologic pressure. 
 Do not use the implant if the Tyvek lid on the blister tray has been opened or the 
packaging appears damaged.  In such cases, the sterility of the implants may be compromised.   
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 77 of 91 
 

 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 78 of 91 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 79 of 91 
24. APPENDIX G – ARTIFICIAL TEARS PACKAGE INSERT 
 
 
 
 
col No.: 
09 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 81 of 91 

 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 83 of 91 
25. APPENDIX H – ASSIGNING SUBJECT NUMBERS AND KITS  
Subject and kit numbers will be dispensed using in accordance with detailed instructions provided separate ly. The investigator or his/ her designee must access the 
electronic data base to obtain detail s of subject randomi zation and kit use. 
    
 
CLINICAL PROTOCOL 
Date:  Phase:  Protocol No.: 
September 16, 2016 Phase II Study GC-009 
 
CR-0412-2015 Rev 2 CONFIDENTIAL   page 91 of 91 
baseline, Week 1-2 (10 day ± 3), Week 12 and Month 12 examinations, blood 
samples will be obtained from each study subject at a lab in close proximity to the investigational site. 
 
 